REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Your initial choice is important when treating multiple myeloma.1

The first response is typically longest for patients with MM.2

MM Response Over Time Graph
  • Image adapted from: Hajek R. Multiple Myeloma - A Quick Reflection on the Fast Progress. InTech Open; 2013.

Survival is adversely affected by each relapse.1

  • MM, multiple myeloma.

References: 1. Anderson KC. Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw. 2013;11(5 suppl):676-679. 2. Hajek R. Strategies for the treatment of multiple myeloma in 2013: moving toward the cure. In: Hajek R, ed. Multiple Myeloma. IntechOpen; 2013. doi:10.5772/55366.

See how REVLIMID works.

View Mechanism of Action

Learn about the IMiD® FOUNDATION.

Explore Sequencing